#TuluTo8thSchedule trends on Twitter as Tuluvas take fight to social media

Mangaluru, Mar 29: Dakshina Kannada Co-operative Milk Producers’ Union Limited in a statement announced that their milk collection centres across Dakshina Kannada and Udupi districts will be closed on March 29 and 30.

Due to a shortage of storage space with them, the Union has decided to stop collecting milk on these two days, according to the statement issued here on Saturday.

The sale/retail of milk and milk products won’t be affected in these two days.

Bengaluru, Mar 25: Karnataka Minister Dr K Sudhakar has been allocated all matters related to COVID-19 by the Governor on the advice of Chief Minister BS Yediyurappa.
Health Minister B Sriramulu, who earlier handled matters related to COVID-19, has been allotted the Backward Class Welfare Development portfolio.
Karnataka on Monday announced a complete lockdown in the state till April 1.
"In the wake of the coronavirus outbreak, the entire state will be locked down from 12 o'clock night of March 23 to April 1. People are requested to strictly follow it to contain the coronavirus spread," Yediyurappa had said.

Beijing/Zurich, Mar 4: China has approved the use of Swiss drugmaker Roche's anti-inflammation drug Actemra for patients who develop severe complications from the coronavirus as it urgently hunts for new ways to combat the deadly infection that is spreading worldwide.

China is hoping that some older drugs could stop severe cytokine release syndrome (CRS), or cytokine storms, an overreaction of the immune system which is considered a major factor behind catastrophic organ failure and death in some coronavirus patients.

Actemra, a biologic drug approved in 2010 in the United States for rheumatoid arthritis (RA), inhibits high Interleukin 6 (IL-6) protein levels that drive some inflammatory diseases.

China's National Health Commission said in treatment guidelines published online on Wednesday that Actemra can now be used to treat coronavirus patients with serious lung damage and high IL-6 levels.

Separately, researchers in the country are testing Actemra, known generically as tocilizumab, in a clinical trial expected to include 188 coronavirus patients and running until May 10.

Roche, which donated 14 million yuan ($2.02 million) worth of Actemra during February, said the trial was initiated independently by a third party with the aim of exploring the efficacy and safety of the drug in coronavirus patients with CRS.

It added that there was currently no published clinical trial data on the drug's safety or efficacy against the virus.

More than 3,000 people have died and 93,000 have been infected by the novel coronavirus thought to have originated in Wuhan, China, before spreading to around 90 countries including the United States, Italy, Switzerland, France and Germany.

The Swiss company, for which China is its No. 2 market behind the United States, also makes diagnostic gear to detect the coronavirus.

Since Actemra's approval a decade ago, it has become a go-to drug against other inflammatory conditions, including cytokine storms in cancer patients receiving cell therapies from Novartis and Gilead Sciences.

In 2012 it helped save the life of a young U.S. girl, the first child to be treated for leukaemia with Novatis' Kymriah, from a post-treatment rush of IL-6.

Priced at between $20-30,000 annually for RA according to SSR Health, Roche's medicine is also used for rare juvenile arthritis and giant cell arteritis, or inflammation of the blood vessels.